E-DRUG: Recent publications on AMR
-----------------------------------
Please, I would like to share the following message with fellow
e-druggers.
Thank you,
Dr Sam Orubu
Antimicrobial resistance (AMR) containment demands new antibiotics as
well as the stewardship of existing ones. I would like to share the
following two publications which I believe would be of interest to all -
students, researchers, and policy makers - in the AMR containment space:
Access to new antibiotics developed between 2010 and 2020 under the
10x20 initiative: Outterson et al show that new antibiotics have launch
lags in the order of several years even in high income countries,
predicating much longer lags in low and middle-income countries (LMICs).
Of 18 new antibiotics, the majority had only been launched in the US,
UK, and Sweden as of January 1, 2021.
Outterson_ K, _Orubu_ ESF, Rex J, Årdal C, Zaman MH. Patient Access in
14 High-Income Countries to New Antibacterials Approved by the US Food
and Drug Administration, European Medicines Agency, Japanese
Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020.
[1] Clinical Infectious Diseases. Clinical Infectious Diseases [in
press] doi: 10.1093/cid/ciab612
A framework for accessing access and use of antimicrobials for policy
and practice interventions on stewardship in LMICs: Orubu et al propose
an innovate lean method for supply chain analysis comprising mapping and
the use of 16 indicators to identify gaps for interventions targeting
stewardship.
E.S.F. _Orubu_, M.A. Samad, M.T. Rahman, M.H. Zaman and V.J. _Wirtz_.
Mapping the Antimicrobial Supply Chain in Bangladesh: A
Scoping-Review-Based Ecological Assessment Approach [2]._Global Health_:
_Science and Practice_ August 2021 doi.org/10.9745/GHSP-D-20-00502
Links:
[1]
https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab612/6319400?redirectedFrom=fulltext
[2] https://www.ghspjournal.org/content/early/2021/08/24/GHSP-D-20-00502
Comments and feedback on these publications are welcome.
Thank you,
Sam
Samuel Orubu, PhD
Post-doctoral associate
Social Innovation on Drug Resistance (SIDR)
Boston University; Boston, MA, USA.
Lecturer,
Faculty of Pharmacy, Niger Delta University, Bayelsa State, Nigeria
samuelorubu@lycos.com